Palatin Technologies Inc (PTN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palatin Technologies Inc (PTN) has a cash flow conversion efficiency ratio of 0.838x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.35 Million) by net assets ($-6.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Palatin Technologies Inc's balance sheet to measure how much of total assets are equity-financed.
Palatin Technologies Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Palatin Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PTN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Palatin Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palatin Technologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sherborne Investors Guernsey C Ltd
LSE:SIGC
|
-0.005x |
|
Ocean Sun As
OL:OSUN
|
-0.298x |
|
Redcentric
LSE:RCN
|
0.133x |
|
BLACK PEARL ZY-10
F:7ZX
|
-0.011x |
|
EZGO Technologies Ltd
NASDAQ:EZGO
|
-0.047x |
|
Silver Predator Corp
V:SPD
|
-0.013x |
|
GENERIC GOLD CORP.
F:1WD
|
N/A |
|
Atlantis S.A.
WAR:ATS
|
0.155x |
Annual Cash Flow Conversion Efficiency for Palatin Technologies Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Palatin Technologies Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Palatin Technologies Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $-111.50K | $-31.46 Million | 282.173x | +233.12% |
| 2023-06-30 | $134.07K | $-28.42 Million | -211.967x | -11423.83% |
| 2022-06-30 | $16.27 Million | $-29.92 Million | -1.839x | -303.25% |
| 2021-06-30 | $49.65 Million | $-22.65 Million | -0.456x | -188.49% |
| 2020-06-30 | $80.17 Million | $41.33 Million | 0.515x | +337.94% |
| 2019-06-30 | $100.55 Million | $-21.78 Million | -0.217x | -443.00% |
| 2018-06-30 | $26.96 Million | $1.70 Million | 0.063x | +102.53% |
| 2017-06-30 | $-5.16 Million | $12.88 Million | -2.494x | -192.61% |
| 2016-06-30 | $-17.59 Million | $-47.36 Million | 2.693x | +346.07% |
| 2015-06-30 | $12.20 Million | $-13.36 Million | -1.095x | +12.23% |
| 2014-06-30 | $9.79 Million | $-12.21 Million | -1.247x | -109.95% |
| 2013-06-30 | $22.98 Million | $-13.65 Million | -0.594x | +92.98% |
| 2012-06-30 | $1.83 Million | $-15.49 Million | -8.459x | -1295.05% |
| 2011-06-30 | $18.19 Million | $-11.03 Million | -0.606x | +1.39% |
| 2010-06-30 | $9.32 Million | $-5.73 Million | -0.615x | +62.57% |
| 2009-06-30 | $3.31 Million | $-5.44 Million | -1.643x | +47.69% |
| 2008-06-30 | $6.55 Million | $-20.58 Million | -3.141x | -163.94% |
| 2007-06-30 | $18.53 Million | $-22.05 Million | -1.190x | +7.13% |
| 2006-06-30 | $18.30 Million | $-23.45 Million | -1.281x | -133.44% |
| 2005-06-30 | $9.23 Million | $-5.06 Million | -0.549x | +55.18% |
| 2004-06-30 | $19.39 Million | $-23.74 Million | -1.225x | -14.86% |
| 2003-06-30 | $18.66 Million | $-19.89 Million | -1.066x | +29.55% |
| 2002-06-30 | $8.69 Million | $-13.15 Million | -1.513x | -114.75% |
| 2001-06-30 | $11.92 Million | $-8.40 Million | -0.705x | +43.02% |
| 2000-06-30 | $6.91 Million | $-8.54 Million | -1.237x | +96.43% |
| 1999-06-30 | $300.00K | $-10.40 Million | -34.667x | -1492.79% |
| 1998-06-30 | $3.40 Million | $-7.40 Million | -2.176x | -420.23% |
| 1997-06-30 | $9.80 Million | $-4.10 Million | -0.418x | +56.18% |
| 1996-06-30 | $2.84 Million | $-2.71 Million | -0.955x | -- |
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more